OPTIMIZE 5.5 - Optimizing Impella 5.5 Outcomes Through Advanced Data Science

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorMedical University of Vienna

About this trial

The main goal of this observational, study is to develop a clinical decision support tool utilizing Impella 5.5 pump parameters to predict native heart recovery and prevent adverse events, by leveraging data science and real-world clinical data of cardiogenic shock patients.

Therefore, secondary objectives are essential to consolidating a retrospective longitudinal analysis of Impella 5.5 pump data alongside ICU digital health record datasets to:

1. Validate the Impella 5.5 placement signal by comparing it with ICU arterial line waveforms. 2. Integrate pump data with ICU clinical data to identify patterns associated with therapy outcomes, including native heart recovery, heart replacement therapy, and mortality while on device support. 3. Define clinical scenarios linked to hemolysis, HRAEs, and arrhythmias and develop predictive models to mitigate their occurrence.

Eligibility criteria

Qualifiers

Adult patients who were treated for cardiogenic shock and supported with an Impella 5.5 micro-axial flow pump

Only patients with available high-resolution pump data (downloaded from the clinical console) and ICU digital health record datasets

Disqualifiers

Patients supported with an Impella 5.5 for indications other than cardiogenic shock (e.g., protected PCI or CABG)

Patients younger than 18 years

Patients with incomplete data, procedural records, or demographic information

Trial design

Treatments tested in this trial

  • Micro-axial flow pump support

Treatment groups

100 Participants
are divided into 3 treatment groups

Sponsors and collaborators